Burghaus Lothar, Madlener Marie, Kohle Felix, Bruno Emanuel F, Limmroth Volker, Fink Gereon R, Malter Michael P
Department of Neurology, Heilig Geist-Hospital, Cologne, Germany.
Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
J Clin Neurol. 2023 Jul;19(4):365-370. doi: 10.3988/jcn.2022.0302.
Status epilepticus (SE) is a neurological emergency due to prolonged seizure activity or multiple seizures without full recovery in between them. Prehospital SE management is crucial since its duration is correlated with higher morbidity and mortality rates. We examined the impact of different therapeutic strategies in the prehospital setting with a focus on levetiracetam.
We initiated the Project for SE in Cologne, a scientific association of all neurological departments of Cologne, the fourth-largest city in Germany with around 1,000,000 inhabitants. All patients with an SE diagnosis were evaluated over 2 years (from March 2019 to February 2021) to determine whether prehospital levetiracetam use had a significant effect on SE parameters.
We identified 145 patients who received initial drug therapy in the prehospital setting by professional medical staff. Various benzodiazepine (BZD) derivatives were used as first-line treatments, which were mostly used in line with the recommended guidelines. Levetiracetam was regularly used (=42) and mostly in combination with BZDs, but no significant additional effect was observed for intravenous levetiracetam. However, it appeared that the administered doses tended to be low.
Levetiracetam can be applied to adults with SE in prehospital settings with little effort. Nevertheless, the prehospital treatment regimen described here for the first time did not significantly improve the preclinical cessation rate of SE. Future therapy concepts should be based on this, and the effects of higher doses should in particular be reexamined.
癫痫持续状态(SE)是一种神经急症,由长时间的癫痫发作活动或多次发作且发作间期无完全恢复所致。院前SE管理至关重要,因为其持续时间与更高的发病率和死亡率相关。我们研究了不同治疗策略在院前环境中的影响,重点关注左乙拉西坦。
我们启动了科隆SE项目,科隆是德国第四大城市,约有100万居民,该项目是科隆所有神经科的科学协会。对所有SE诊断患者进行了为期2年(2019年3月至2021年2月)的评估,以确定院前使用左乙拉西坦是否对SE参数有显著影响。
我们确定了145例在院前环境中接受专业医务人员初始药物治疗的患者。各种苯二氮䓬(BZD)衍生物被用作一线治疗药物,大多按照推荐指南使用。左乙拉西坦被常规使用(=42例),且大多与BZDs联合使用,但静脉注射左乙拉西坦未观察到显著的额外效果。然而,所给药剂量似乎偏低。
左乙拉西坦可在院前环境中轻松应用于成人SE患者。尽管如此,此处首次描述的院前治疗方案并未显著提高SE的临床前终止率。未来的治疗理念应基于此,尤其应重新审视更高剂量的效果。